Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06646289 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Sponsor changed: Janssen Research & Development, LLC to MeiraGTx Ocular UK Ltd
    • Eligibility criteria expanded, about 3 words
  2. 6 versions Re-verified since Mar 12, 2026, no change to tracked fieldsv18-v23
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 42 to confirmed 24
    • Site details revised at 3 of 3 sites
    v17
  4. Site details revised at 2 of 3 sitesv16
  5. 3 versions Re-verified since Oct 9, 2025, no change to tracked fieldsv13-v15
Show 11 earlier versionsHide 11 earlier versions
  1. Primary endpoints: 1 to 3
    • Enrollment target: 39 to 42
    • Secondary endpoints shortened, about 100 words
    v12
  2. Study sites: 2 to 3v11
  3. 4 versions Re-verified since Mar 29, 2025, no change to tracked fieldsv7-v10
  4. Primary endpoints: 2 to 1
    • Secondary endpoints: 8 to 7
    v6
  5. Study sites: 1 to 2v5
  6. Re-verified, no change to tracked fieldsv4
  7. Enrollment target: 42 to 39v3
  8. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 11, 2024 to Oct 10, 2024
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
Trial Details
NCT Number NCT06646289
Lead Sponsor MeiraGTx Ocular UK Ltd
Conditions
(from sponsor)		 X-Linked Retinitis Pigmentosa
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov